TECLens develops technology to treat keratoconus and correct vision problems.
TECLens has raised $9.3M in total funding. The most recent round was Series A. The last funding was announced in February 2025.
TECLens's investors include Johnson & Johnson Innovation JJDC, Sunmed Capital, Yonjin Venture, Rimonci Capital.
TECLens is headquartered in New York, United States.
TECLens develops technology to treat keratoconus and correct vision problems.
TECLens is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TECLens — Funding & Investors." VCBacked, February 11, 2025, https://www.vcbacked.co/company/teclens. Accessed July 26, 2026.
VCBacked. (2025). TECLens — Funding & Investors. Retrieved July 26, 2026, from https://www.vcbacked.co/company/teclens
{{cite web |title=TECLens — Funding & Investors |url=https://www.vcbacked.co/company/teclens |website=VCBacked |access-date=July 26, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated